Patients with HPV oropharyngeal cancer will live for decades with the sequelae of therapy, including radiation induced second primary cancers (SP). This study reviews and reports the incidence and outcomes of in-field SPs from the Quarterback Trials (QT) where molecular testing confirmed HPV status at diagnosis and recurrence. Patients in the QT had <20 pack-year smoking history, locally advanced disease, and molecularly confirmed HPV status. All patients received TPF induction chemotherapy (IC). Responders were treated on protocol with reduced-dose (RD, 5600 cGy) or standard-dose (SD, 7000 cGy) chemoradiotherapy (CRT). Recurrences and SPs were confirmed by biopsy and molecular testing. Of the 60 eligible patients consented, 13 received SD (8 randomized to SD, 4 with inadequate response to IC, 1 withdrew consent). There were 7 HPV+ LRFs (1 SD, 6 RD) and 4 molecularly confirmed in-field non-HPV SPs (2 SD, 2 RD). All SP tumors were p53-mutated and HPV-negative. Median time to LRF and SP was 8 and 66 months, respectively. Median survival after LRF or SP was 11 months and 18+ months, respectively. Non-HPV SPs are not uncommon in HPV+ non-smoking patients and occurred more frequently with SD treatment, suggesting a radiation dose-dependent effect. SPs presented symptomatically. SPs are likely to become a major cause of mortality in this population over time, underscoring the need for molecular testing to guide surveillance and treatment decisions. This is especially relevant for analysis of outcomes in de-escalation trials.
Background: Human papillomavirus‐positive oropharyngeal squamous cell carcinoma (HPV+ OPC) patients typically exhibit reduced rates of second primary malignancies (SPMs) compared to HPV‐negative head and neck cancer patients. While HPV+ OPC patients may be predisposed to SPMs in HPV‐associated anatomical sites, the metachronous presentation of an HPV+ OPC and subsequent glioblastoma multiforme (GBM) has not been previously documented. Cases: We present two cases of HPV+ OPC patients who developed GBMs within a short period after definitive therapy. Methods: Comprehensive whole exome sequencing (WES) was performed on paired GBM, oropharyngeal, and matched normal tissues from two HPV+ OPC patients who developed GBMs within a short period after definitive therapy, with the goal of identifying shared somatic and germline variants. Bioinformatic analyses included variant calling, annotation, and pathway enrichment. Results: WES revealed a shared CEP104 missense mutation among both oropharyngeal tumors as well as a potential KIR2DL4 germline variant in the second patient, suggesting a possible role for disrupted NK cell immunity in driving these cancers. Conclusion: Although these cases were likely random events, they illustrate the diagnostic and therapeutic challenges of GBM following HPV+ OPC and underscore the importance of personalized genomic assessment in HPV+ OPC survivors, who may develop non‐head and neck SPMs unrelated to field cancerization.